大剂量化疗联合自体造血干细胞移植治疗淋巴瘤的疗效

摘要

Objective:To evaluate the efficacy of autologous hematopoietic stem cell transplantation (ASCT)fol-lowing high dose chemotherapy (HDT)in patients with lymphoma.Methods:All 30 patients with lymphoma were en-rolled in a clinical study carried out in our hospital from December 2009 to December 2015.All patient were treated with autologous hematopoietic stem cell transplantation following high dose chemotherapy.Results:One patient died of serious infection after transplantation,twenty -two patients alived till March 1,2016,nine of thirty patients relapsed, the middle time of relapse was 4.5 (1 ~15)months,six of them died in three years.Transplantation -related mortali-ty was 6.7%.Conclusion:HDT/ASCT is an efficacious and safe therapeutic measure in patients with lymphoma.%目的：观察大剂量化疗联合自体造血干细胞移植治疗恶性淋巴瘤的疗效。方法：选择2009年12月－2015年12月于我科住院治疗的恶性淋巴瘤病例30例，均接受大剂量化疗联合自体造血干细胞移植治疗。结果：1例患者造血干细胞回输后因严重肺部感染死亡，其余均成功植入并快速重建造血；随访至2016年3月1日，有22例存活，无病生存19例，9例复发，中位复发时间为4．5（1～15）个月，其中6例复发后3年内死亡，2例治疗后重新评估为 CR 随访至今未再复发，1例为单一椎体复发至今仍存活。移植相关死亡率为6．7％。结论：大剂量化疗联合自体造血干细胞移植能很快重建造血，是治疗恶性淋巴瘤安全有效的方法。